Webber S. International Diabetes Federation. Diabetes Research and Clinical Practice. vol. 102, 2013. p. 147–148.

Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390–403.

Article  CAS  PubMed  Google Scholar 

Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52(1):124–32.

Article  CAS  PubMed  Google Scholar 

Cornu M, Yang JY, Jaccard E, Poussin C, Widmann C, Thorens B. Glucagon-like peptide-1 protects β-cells against apoptosis by increasing the activity of an Igf-2/Igf-1 receptor autocrine loop. Diabetes. 2009;58(8):1816.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farilla L, Hongxiang H, Bertolotto C, Kang E, Bulotta A, Mario UDI, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143(11):4397–408.

Article  CAS  PubMed  Google Scholar 

Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes. 2001;50(10):2237–43.

Article  CAS  PubMed  Google Scholar 

Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52(1):124–32.

Article  CAS  PubMed  Google Scholar 

Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem. 2008;283(13):8723–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imeryüz N, Yeǧen BÇ, Bozkurt A, Coşkun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol. 1997;273(4):920.

Google Scholar 

Halim MA, Degerblad M, Sundbom M, Karlbom U, Holst JJ, Webb DL, et al. Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans. J Clin Endocrinol Metab. 2018;103(2):575–85. https://doi.org/10.1210/jc.2017-02006.

Article  PubMed  Google Scholar 

De Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 2008;51(12):2263–70.

Article  CAS  PubMed  Google Scholar 

Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52.

Article  CAS  PubMed  Google Scholar 

Aulinger BA, Vahl TP, Prigeon RL, D’Alessio DA, Elder DA. The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact? Am J Physiol Endocrinol Metab. 2016;310(9):E774–81.

Article  PubMed  PubMed Central  Google Scholar 

Grespan E, Giorgino T, Natali A, Ferrannini E, Mari A. Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes. Metabolism. 2021;114:154415.

Article  CAS  PubMed  Google Scholar 

Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717–23.

Article  CAS  PubMed  Google Scholar 

Vilsbøll T, Agersø H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88(1):220–4. https://doi.org/10.1210/jc.2002-021053.

Article  CAS  PubMed  Google Scholar 

Calanna S, Christensen M, Holst JJ, Laferrère B, Gluud LL, Vilsbøll T, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56(5):965.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88(6):2706–13.

Article  PubMed  Google Scholar 

Takahashi T, Shiraishi A. Stem cell signaling pathways in the small intestine. Int J Mol Sci. 2020;21(6):2032.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin X, Farin HF, Van Es JH, Clevers H, Langer R, Karp JM. Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny. Nat Methods. 2014;11(1):106.

Article  CAS  PubMed  Google Scholar 

Shroyer NF, Wallis D, Venken KJT, Bellen HJ, Zoghbi HY. Gfi1 functions downstream of Math1 to control intestinal secretory cell subtype allocation and differentiation. Genes Dev. 2005;19(20):2412–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mori-Akiyama Y, van den Born M, van Es JH, Hamilton SR, Adams HP, Zhang J, et al. SOX9 is required for the differentiation of paneth cells in the intestinal epithelium. Gastroenterology. 2007;133(2):539–46.

Article  CAS  PubMed  Google Scholar 

Katz JP, Perreault N, Goldstein BG, Lee CS, Labosky PA, Yang VW, et al. The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development. 2002;129(11):2619–28.

Article  CAS  PubMed  Google Scholar 

Gehart H, van Es JH, Hamer K, Beumer J, Kretzschmar K, Dekkers JF, et al. Identification of enteroendocrine regulators by real-time single-cell differentiation mapping. Cell. 2019;176(5):1158–117316.

Article  CAS  PubMed  Google Scholar 

Beumer J, Artegiani B, Post Y, Reimann F, Gribble F, Nguyen TN, et al. Enteroendocrine cells switch hormone expression along the crypt-to-villus BMP signalling gradient. Nat Cell Biol. 2018;20(8):909–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nauck MA. The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit–risk relationship. Metabolism. 2020;103:154031. https://doi.org/10.1016/j.metabol.2019.154031.

Article  CAS  PubMed  Google Scholar 

Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia possible contribution to impaired incretin effects in diabetes. Diabetes. 2007;56(6):1551–8. https://doi.org/10.2337/db06-1033.

Article  CAS  PubMed  Google Scholar 

Faerch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, et al. GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO Study. Diabetes. 2015;64(7):2513–25. https://doi.org/10.2337/db14-1751.

Article  CAS  PubMed  Google Scholar 

Watkins JD, Carter S, Atkinson G, Koumanov F, Betts JA, Holst JJ, et al. Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies. Metabolism. 2023;1(140): 155375.

Article  Google Scholar 

Tian F, Wang X, Ni H, Feng X, Yuan X, Huang Q. The ginsenoside metabolite compound K stimulates glucagon-like peptide-1 secretion in NCI-H716 cells by regulating the RhoA/ROCKs/YAP signaling pathway and cytoskeleton formation. J Pharmacol Sci. 2021;145(1):88–96.

Article  CAS  PubMed  Google Scholar 

Filippello A, Di Mauro S, Scamporrino A, Malaguarnera R, Torri